We are pulmonary hypertension professionals united in our vision for a world without pulmonary vascular disease. We believe we can achieve this together, and we won’t stop until we do.
Drug Discovery and Development Symposium 2025
Just over a month to go! With the theme of ‘Inclusive and sustainable drug development for PAH’, the programme is divided into 6 sessions: new standards of care, disease modification, diversity and inclusion, global aspects of drug development and availability, innovations in trial design, and novel drug & device therapies.
We're delighted to announce PVRI 2026 will be taking place in the vibrant and historic city of Dublin. Held in the Dublin Royal Convention Centre (28 - 31 January), we can't wait to see you there! Stay tuned for more details...
Whether you’re a pulmonary hypertension specialist, a pharmaceutical or industry colleague, a regulator, a patient, or a caregiver, joining our growing global family means you share our vision to reduce the global burden of pulmonary vascular disease.
This year’s symposium will bring together regulatory, industry, and academic bodies in the field, offering a unique platform for in-depth discussions, knowledge exchange, and collaboration on the latest drug advancements in PH. Registration is open.
Environmental Determinants and PVDs is part of the Virtual Symposium series by the iPVD, a global education programme that highlights top-notch research on inflammation and infectious PVD.
Lysosomal dysfunction and inflammatory sterol metabolism in pulmonary arterial hypertension
ZENITH trial & a long-term follow-up study of Sotatercept for treatment of Pulmonary Arterial Hypertension: Interim results of SOTERIA. Our Community Call host Katrina Barry, participant in the long-term follow-up study of SOTERIA, joined the discussion with Aaron Waxman to answer any patient-related audience questions
Substantial evidence from animal models supports the concept of inhibiting peripheral serotonin synthesis for the treatment of pulmonary arterial hypertension (PAH), as demonstrated by pharmacological blockade or genetic deletion of tryptophan hydroxylase 1 (TPH1) [1-5]. Most recently, we have shown that daily inhalation of TPT-004, a novel class TPH1 inhibitor, can alleviate PAH in the Sugen-hypoxia (SuHx) rat model [1].
Phenotypic transition of pulmonary artery smooth muscle cells (PASMCs) under hypoxic conditions, which in turn causes increased proliferation and migration capacity, is an important pathological process in Hypoxic pulmonary hypertension (HPH). Although research on the phenotypic transition of PASMCs has been ongoing, little is known about the specific molecular mechanisms underlying this process.
Activin-A is elevated in pulmonary arterial hypertension (PAH) patients, and reportedly suppresses BMPR-II. This suggests one mechanism of action for PAH drug, sotatercept, an activin-ligand trap. However, we were unable to confirm that activin-A reduces BMPR-II in pulmonary endothelial cells. Thus, it seems unlikely that sotatercept influences BMPR-II or PAH via this mechanism.
We’re pleased to share that the Pulmonary Hypertension Global Patient Survey (PHGPS) - a key project of the IDDI Patient Engagement & Empowerment (PE&E) Workstream - is now a stand-alone Task Force.
The PVRI 2025 Annual Congress was hosted in the vibrant city of Rio de Janeiro at the Windsor Convention & Expo Centre. Esteemed experts, healthcare professionals, and researchers from around the globe gathered in this iconic city to share groundbreaking insights, foster collaborations, and advance our collective mission towards conquering PVD.
Rubin Tuder, a trailblazer in the field of pulmonary vascular biology and a driving force in PH research, has been honoured with the PVRI Lifetime Achievement Award for 2025. This prestigious Award is given annually at the PVRI Annual Congress to a senior PH investigator or clinician for their exceptional and outstanding contributions to the field of pulmonary vascular disease and to PVRI. This recognition celebrates his unparalleled contributions to science, mentorship, and the global PH community.
The Burke Advanced Fellowship in Pulmonary Heart Disease at The Brigham and Women’s Hospital and Harvard Medical School—invites applications for an advanced fellowship in pulmonary heart disease starting July 1, 2026. This training program is sponsored by the Center for Pulmonary Heart Disease at the Brigham and Women’s Hospital. The position offers an intensive clinical experience including evaluation and management of both inpatients and outpatients with pulmonary vascular disease and right heart dysfunction or failure. In addition, applicants are strongly encouraged to participate in a translational or clinical research program.
